港股異動 | 微創醫療(0853.HK)漲超9% 時隔3個半月重回20港元
格隆匯6月21日丨微創醫療(0853.HK)大幅拉昇漲9.28%,報20.5港元創3個半月新高價,成交額放大至3.3億港元,總市值超370億港元。微創腦科學已於近日通過聯交所上市聆訊,預期將集資約5000萬美元,聯席保薦人為摩根大通及中金公司。聆訊後資料顯示,微創腦科學為中國神經介入醫療器械公司,現時共擁有30款產品。根據灼識諮詢的資料,就2020年的收入而言,公司為該市場前五大參與者中唯一的中國公司,並擁有約4%的市場份額。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.